
Cancer drug resistance, a major therapeutic challenge, often arises from overactive ABC transporters such as ABCB1, ABCG2, and ABCC1. Recent advances in structural, biophysical, and in silico studies have shed light on how these transporters expel drugs from cancer cells. Promising strategies like immune and thermal therapies, as well as nanomedicine, have emerged to combat this resistance. This review examines the latest five years' progress in understanding these clinically significant transporters, exploring their broad substrate specificity and innovative approaches to inhibit them.
Like
Save
Share